US Stock MarketDetailed Quotes

INTS Intensity Therapeutics

Watchlist
  • 0.5729
  • +0.0139+2.49%
Close May 2 16:00 ET
  • 0.5700
  • -0.0029-0.51%
Post 20:01 ET
8.75MMarket Cap-0.49P/E (TTM)

About Intensity Therapeutics Company

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Company Profile

SymbolINTS
Company NameIntensity Therapeutics
Listing DateJun 30, 2023
Issue Price5.00
Founded2012
CEOMr. Lewis H. Bender
MarketNASDAQ
Employees16
Fiscal Year Ends12-31
Address1 Enterprise Drive,Suite 430
CityShelton
ProvinceConnecticut
CountryUnited States of America
Zip Code06484-4779
Phone1-203-221-7381

Company Executives

  • Name
  • Position
  • Salary
  • Lewis H. Bender
  • President, Chief Executive Officer and Chairman of the Board
  • 2.49M
  • Joseph Talamo
  • Chief Financial Officer
  • 1.66M
  • John Wesolowski
  • Principal Accounting Officer and Controller
  • 569.13K
  • Thomas I.H. Dubin
  • Director
  • 214.95K
  • Daniel J. Donovan
  • Independent Director
  • 265.72K
  • Dr. Mark A. Goldberg, M.D.
  • Independent Director
  • 270.22K
  • Dr. Emer Leahy, PhD
  • Independent Director
  • 270.22K

Market Insights

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.